GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
In this cohort study of individuals with T2D, GLP-1 RA use was associated with a modestly increased risk of incident DR; however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.
Authors
- David J. Ramsey (ORCID: https://orcid.org/0000-0002-5504-812X)
- Sourbha S. Dani (ORCID: https://orcid.org/0000-0002-3434-6136)
- Anju Nohria
- Manav Patel
- Sumanth Khadke (ORCID: https://orcid.org/0000-0002-7262-6905)
- Kathryn Moynihan Ramsey (ORCID: https://orcid.org/0000-0002-0691-7835)
- Sarju Ganatra (ORCID: https://orcid.org/0000-0003-0296-6864)
- Ashish Kumar
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Javed Butler (ORCID: https://orcid.org/0000-0003-4267-6933)
- Tirth Patel
- Mikhail Kosiborod
- Jui Shah (ORCID: https://orcid.org/0009-0006-7518-8361)
- Bhargav Makwana
- Krisha Panchal
Institutions
- Northwestern University (US)
- Tufts University (US)
- Brigham and Women's Hospital (US)
- Lahey Hospital and Medical Center (US)
- Mayo Clinic (US)
- Harvard University (US)
- New England College of Optometry (US)
- Ronald Reagan UCLA Medical Center (US)
- University of Mississippi (US)
- Lahey Medical Center (US)
- Saint Luke's Hospital (US)
- Baylor Scott & White Health (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.26321
- Citations
- 29
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 37.55